Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel

Abstract: Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, inc...

Full description

Saved in:
Bibliographic Details
Main Authors: Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Zhen-Huan Hu, Michael T. Hemmer, Michael J. Zoratti, Suresh Vunnum, Jonathan Tsang, Clare Spooner, Harry Smith, Christine Fu, Anik Patel, Harry Miao, Shilpa A. Shahani, Debbie L. Mirjah, Hairong Xu, Marcelo C. Pasquini
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S247395292500062X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items